Assessment of risk perception of patients concerning adverse drug reactions

Author:

Joaquim João José12ORCID,Matos Cristiano1ORCID,Mateos-Campos Ramona3ORCID

Affiliation:

1. 1 Pharmacy, Polytechnic Institute of Coimbra, Coimbra Health School , Portugal

2. 2 Department of Pharmaceutical Sciences, Faculty of Pharmacy , University of Salamanca , Spain

3. 3 Area of Preventive Medicine and Public Health , Department of Biomedical and Diagnostic Sciences , University of Salamanca , Spain

Abstract

Abstract Introduction. The use of medicines involves trade-offs between their therapeutic benefits and inherent risks. Several studies show that numerous adverse drug reactions (ADRs) could be avoided by increasing patients’ awareness of medicine’s risks. Even though drug labels enclose relevant information about risks and benefits, this information often requires patient education and overall health literacy to improve medication adherence, thereby preventing ADR frequency. Aim. To describe patient awareness of ADR risks and the Portuguese Pharmacovigilance System. Methods. A questionnaire comprising 27 questions was conducted at a health centre in Coimbra, Portugal. This study included ninety-one patients. Risk perception was scored as positive (≥2.5 points) or negative (<2.5 points). Results were analysed by SPSS v 27.0. Results. This work highlights poor patient perceptions of risk with a rate of negative responses of 85,7%. Although some responders were aware of the possibility of reporting ADRs, only some participants were familiar with the Portuguese Pharmacovigilance System. Additionally, only five patients – out of the vast majority of those who had previously encountered ADRs – reported the event to INFARMED. Conclusion. Patient low literacy regarding ADRs and the national reporting systems need to be urgently improved. Patient-centred communication strategies for recognising regulatory requirements and standards of product safety are important measures to achieve effective awareness through routine reporting within the Pharmacovigilance systems.

Publisher

Walter de Gruyter GmbH

Subject

Pharmacology,Molecular Biology,General Medicine,Biochemistry

Reference33 articles.

1. EC. Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmaco-vigilance. Directive 2001/83/EC on the Community code relating to medicinalproducts for human us. [http://eur-lex.europa. eu/LexUriServ/LexUriServ; 2010]

2. World Health Organization. The importance of pharmacovigilance: safety monitoring of medicinal products. Geneva: WHO; 2002:1-48.

3. Vilhelmsson A, Svensson T, Meeuwisse A, Carlsten A. Experiences from consumer reports on psychiatric adverse drug reactions with antidepressant medication: a qualitative study of reports to a consumer association. BMC Pharmacol Toxicol. 2012;13(1):19.

4. Herdeiro MT, Ferreira M, Ribeiro-Vaz I, Polónia JJ, Costa Pereira A. O Sistema Português de Farmacovigilância. Acta Med Port. 2012; 25(4).

5. Matos C, van Hunsel F, Joaquim J. Are consumers ready to take part in the Pharmacovigilance System? - a Portuguese preliminary study concerning ADR reporting. Eur J Clin Pharmacol. 2015;883-90.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3